The FDA advisory panel voted unanimously 10-0 that Grail Inc.'s Galleri test is safe, but voted narrowly 6-4 that there is reasonable assurance the test is effective.

From the articleGrail multicancer detection test wins FDA advisers’ backingAlso in FDA advisory panel endorses Grail blood test for cancer, saying benefits outweigh risks, Grail multicancer detection test wins FDA advisers’ backing, FDA Panel Narrowly Backs Multi-Cancer Blood Test Despite Doubts It Works